We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

2 hedge funds and large institutions have $3.56M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

27% less capital invested

Capital invested by funds: $4.9M → $3.56M (-$1.34M)

90% less call options, than puts

Call options by funds: $7K | Put options by funds: $68K

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
$7K
Puts
$68K
Net Calls
-$61K
Net Calls Change
-$163K

Top Buyers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
+$1.52M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$1.66M
2
RCM
Rotella Capital Management
Washington
-$80K
3
HCM
Highlander Capital Management
New Jersey
-$43.8K
4
RC
Randolph Company
Ohio
-$16K
5
TRCT
Tower Research Capital (TRC)
New York
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.15M – – –
SCM
2
Sarissa Capital Management
Connecticut
$1.03M +$1.52M +1 New
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$315K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$169K – – –
BFA
5
BlackRock Fund Advisors
California
$124K – – –
VKH
6
Virtu KCG Holdings
New York
$112K – – –
SIM
7
Spark Investment Management
New York
$74K – – –
Northern Trust
8
Northern Trust
Illinois
$64K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$58K – – –
CC
10
Callan Capital
California
$56K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$54K – – –
Group One Trading
12
Group One Trading
Illinois
$52K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$50K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$39K – – –
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$38K – – –
Bank of America
16
Bank of America
North Carolina
$27K – – –
RG
17
Rathbones Group
United Kingdom
$25K – – –
Citadel Advisors
18
Citadel Advisors
Florida
$21K – – –
Hudson Bay Capital Management
19
Hudson Bay Capital Management
Connecticut
$18K – – –
BA
20
BlackRock Advisors
Delaware
$17K – – –
State Street
21
State Street
Massachusetts
$11K – – –
FANJ
22
Financial Architects (New Jersey)
New Jersey
$10K – – –
UBS Group
23
UBS Group
Switzerland
$10K – – –
NPC
24
National Planning Corporation
California
$7.07K – – –
AIG
25
American International Group
New York
$6.13K – – –
1
2

SEEL Hedge Fund Activity: Q4 2014 in Review

2 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2014, worth a combined $3.56M — down 27% from $4.9M a quarter earlier.

Fund positioning in SEEL was balanced in Q4 2014: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $1.52M. The largest seller was Visium Asset Management, exiting entirely with an estimated $1.66M sold.

  • 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $3.56M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2014, down 27% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2014 and 1 closed out, a net change of 0 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2014 was Sarissa Capital Management, an estimated $1.52M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2014 was Visium Asset Management, an estimated $1.66M sold.

Based on aggregated 13F filings for Q4 2014.